October 30, 2021 : Issue #1172

TOP STORIES — Diabetes News and Research

57th EASD: Pramlintide and Prandial Insulin for Type 1 Diabetes

57th EASD: Hypoglycemia Risk With A Once-weekly Basal Insulin

Obstructive Sleep Apnea Severity and the Development of T2D

Is Liraglutide Effective for Patients with Type 1 Diabetes?

Are Current Hypertension Goals Successful in Reducing Cardiovascular Risk in Patients with Diabetes?

Benefits of Tethered Combination Therapy for Type 2 Diabetes

It has been almost 15 years since Symlin (pramlintide) was first approved as an amylin replacement. Amylin is a hormone that is produced in the beta cells of the pancreas and works to prolong gastric emptying time, reduce postprandial glucagon secretion, and reduce caloric intake. When a patient develops type 1 diabetes, they lose the ability to produce insulin as well as amylin. This makes glucose control much harder. I remember when Amylin brought Symlin to market, and how many of us viewed this as a great product for type 1 patients. There were two things that affected the use of Symlin. You could not mix it with insulin, so that meant 2-3 extra shots a day; and Amylin brought Byetta to England that same year, and attention turned to the once a day shot.

Although Byetta and the other GLP-1 Analogs have enjoyed great success with type 2 patients, they have never been approved in type 1 patients.

Our intern Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy, has found that there is a new product under research that combines a prandial insulin with pramlintide in one injection. If this combo is approved, it will definitely make a difference in many patients with type 1 diabetes. Click here to review yourself (Laterpay feature).

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

In managing type 1 diabetes, a single combined formulation of pramlintide and prandial insulin can provide multiple benefits.

Insulin icodec is a novel once-weekly basal insulin analog for patients with type 2 diabetes.

Treating obstructive sleep apnea can decrease catecholamine, increase insulin sensitivity, and decrease pancreatic beta-cell apoptosis, leading to a lower risk of developing T2D.

What if there is an adjunct option in managing type 1 diabetes beyond insulin analogs in the form of GLP-1 RAs?

This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk. 

Tethered combination therapy for type 2 diabetes could be more beneficial than two medications taken concurrently.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Dalia Elabed, PharmD Candidate 2022, University of South Florida Taneja College of Pharmacy

Destiny Funchess, PharmD Candidate, Tougaloo College, South College School of Pharmacy

Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022

Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy

Your Friends in Diabetes Care
Steve and Dave

Diabetes In Control
www.diabetesincontrol.com